Preclinical studies indicate that anti‐HER2 therapy can upregulate tumor cell PD‐L1 expression, for instance, via the interferon‐γ pathway, potentially representing an adaptive immune evasion mechanism. The gene discussed is ERBB2; the disease is neoplasm.